Last reviewed · How we verify
Test (T)
Testosterone replacement therapy
Testosterone replacement therapy Used for Hypogonadism, Delayed puberty.
At a glance
| Generic name | Test (T) |
|---|---|
| Sponsor | The Affiliated Hospital of Qingdao University |
| Drug class | Androgen |
| Target | Androgen receptor |
| Modality | Small molecule |
| Therapeutic area | Endocrinology |
| Phase | FDA-approved |
Mechanism of action
Testosterone replacement therapy involves administering exogenous testosterone to replace deficient levels in the body, which can help alleviate symptoms of hypogonadism such as low libido, fatigue, and decreased muscle mass.
Approved indications
- Hypogonadism
- Delayed puberty
Common side effects
- Acne
- Erythrocytosis
- Sleep apnea
- Edema
- Gynecomastia
Key clinical trials
- Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial (PHASE1)
- Population Based Germline Testing for Early Detection and Prevention of Cancer (NA)
- Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma (PHASE2)
- Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN (PHASE1, PHASE2)
- Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer (PHASE1)
- Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors (PHASE1)
- Nivolumab and Ipilimumab in Treating Patients With Rare Tumors (PHASE2)
- Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Test (T) CI brief — competitive landscape report
- Test (T) updates RSS · CI watch RSS
- The Affiliated Hospital of Qingdao University portfolio CI